WHO Member States continue negotiations on the Pathogen Access and Benefit Sharing Annex

WHO Member States have significantly advanced negotiations on the Pathogen Access and Benefit Sharing (PABS) annex, a pivotal component of the proposed WHO Pandemic Agreement, during their recently concluded seventh meeting of the Intergovernmental Working Group (IGWG) in Geneva. While substantial progress was reported, delegations universally acknowledged that continued, intensive discussions are essential to finalize a comprehensive framework designed to facilitate a faster, more effective, and profoundly equitable global response to future pandemics. This crucial annex aims to establish a robust mechanism for the rapid sharing of pathogens with pandemic potential, alongside ensuring the fair and equitable distribution of benefits derived from their use, encompassing vital pandemic countermeasures such as vaccines, diagnostics, and therapeutics.

The Crucial Role of Pathogen Access and Benefit Sharing (PABS)

The concept of Pathogen Access and Benefit Sharing lies at the heart of the envisioned WHO Pandemic Agreement, serving as a cornerstone for global health security. Its fundamental premise is to build trust among nations, particularly between those with advanced scientific and manufacturing capabilities and those in regions frequently serving as epicenters for emerging pathogens. During the seventh IGWG meeting, which concluded on March 1, 2024, Member States reaffirmed their unwavering commitment to developing a PABS system that addresses the historical inequities observed during past health crises. The system is designed to incentivize countries to rapidly share pathogen samples and their genetic sequence information, knowing that such transparency and cooperation will be reciprocated with tangible benefits. This reciprocal arrangement is deemed vital, as the hesitation of any single nation to share critical data can severely impede the global scientific community’s ability to understand, track, and develop countermeasures against novel threats.

Discussions during the two-week session meticulously streamlined the draft text, with delegates engaging in consultations on more intricate and politically sensitive issues to foster broader consensus. Key elements of the PABS system that were extensively debated included the precise nature of contractual arrangements underpinning the framework, the structural design and operational protocols of the laboratory networks responsible for the secure sharing and handling of pathogens and their invaluable sequence information, and critically, the comprehensive definition of what constitutes "benefits" arising from pathogen sharing. This definition is central to ensuring that the agreement delivers on its promise of equity, moving beyond mere declarations to actionable mechanisms for resource distribution and capacity building.

A History of Global Health Governance: From IHR to the Pandemic Agreement

The push for a new international accord on pandemics stems directly from the stark lessons learned during the COVID-19 pandemic. While the International Health Regulations (IHR) of 2005 provided a foundational legal framework for global health security, focusing on surveillance, reporting, and coordinated response to acute public health events, their limitations became glaringly apparent. The IHR, for instance, lacked strong mechanisms for equitable access to medical countermeasures, often relying on voluntary cooperation rather than binding obligations. During COVID-19, this led to rampant "vaccine nationalism," where wealthier nations secured disproportionate shares of vaccines, diagnostics, and personal protective equipment, leaving many low- and middle-income countries struggling to protect their populations. Data from Oxfam and the People’s Vaccine Alliance highlighted this disparity, showing that by early 2022, only 11% of people in low-income countries had received at least one vaccine dose, compared to over 70% in high-income nations.

Recognizing these systemic failures, a special session of the World Health Assembly (WHA) was convened in December 2021, marking a historic decision to establish an intergovernmental negotiating body (INB) to draft and negotiate a new convention, agreement, or other international instrument under the Constitution of the WHO. This initiative, later termed the WHO Pandemic Agreement, aimed to strengthen international cooperation and address critical gaps in pandemic prevention, preparedness, and response that the IHR could not fully cover. The mandate specifically included the development of a comprehensive Pathogen Access and Benefit Sharing system, recognizing it as indispensable for fostering global solidarity and ensuring that the benefits of scientific advancements are shared globally, rather than concentrated in a few hands. The IGWG, established by resolution WHA78.1 (likely WHA75.9 in May 2022, given the updated timeline), was tasked with undertaking these complex negotiations, with the ultimate goal of presenting a finalized agreement to the World Health Assembly for adoption.

Navigating Complexities: Key Discussion Points and Hurdles

The discussions surrounding the PABS annex are fraught with technical, legal, and political complexities, reflecting the diverse interests and capabilities of WHO’s 194 Member States. One of the most contentious areas revolves around the contractual arrangements that will underpin the PABS framework. This includes determining the precise legal nature of pathogen sharing agreements, whether they will be standardized, bilateral, or multilateral, and how they will be enforced across different national jurisdictions. The question of intellectual property rights (IPR) remains a significant hurdle. Pharmaceutical companies and developed nations often emphasize the need to protect IPR to incentivize innovation and recoup substantial research and development costs, which can run into billions of dollars for a single vaccine or drug. Conversely, developing nations and public health advocates argue that during a pandemic, public health imperatives should supersede commercial interests, advocating for compulsory licensing, patent pools, or waivers to ensure equitable access.

Furthermore, defining "benefits" is a multifaceted challenge. While obviously including vaccines, diagnostics, and therapeutics, benefits could also encompass technology transfer, local manufacturing capacity building, training of healthcare workers, financial contributions to a global pandemic fund, and access to scientific data and research findings. The modalities of benefit sharing – whether through tiered pricing, donations, royalty payments, or mandatory transfers – are all subject to intense negotiation. The structure of global laboratory networks, including WHO reference laboratories and national public health labs, is another critical component. Ensuring these networks are robust, secure, and capable of rapid pathogen sequencing and sharing, while adhering to strict biosafety and biosecurity protocols, requires significant investment and harmonized standards. The discussion also touches upon the relationship between physical pathogen samples and their digital sequence information (DSI), with debates on whether DSI should be treated similarly to physical samples for benefit-sharing purposes. This particular debate has implications for open science versus commercial exploitation of genetic resources.

Voices from the Frontlines: Official Statements and Stakeholder Perspectives

Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, consistently emphasized the urgency and moral imperative of finalizing the agreement. "I commend Member States for their continued dedication to multilateralism, dialogue and to finding common ground," he stated following the IGWG meeting. "While differences remain, those differences can be bridged if we keep our shared goal in sight: a world where pathogens and scientific information are shared rapidly, and the benefits they generate are shared fairly and equitably. The task is vital, and urgent. The next pandemic will not wait. Neither should we." His remarks underscore the high stakes and the political will required to overcome remaining obstacles.

The IGWG Bureau Co-Chairs also conveyed a message of determined progress. Ambassador Tovar da Silva Nunes of Brazil noted, "Over the past two weeks, we have made meaningful progress on some of the most technically and politically complex elements of the PABS annex. The remaining issues are challenging, but we have a clear path to completing this important work." Echoing this sentiment, Mr. Matthew Harpur added, "The progress made at this meeting reflects our shared determination to deliver an effective, robust and equitable PABS system. With continued momentum, we can finalize an annex that strengthens global pandemic prevention, preparedness and response."

Beyond the official statements, various stakeholders closely monitor the negotiations. Developing nations, represented by blocs like the African Group and others from the Global South, advocate strongly for robust and legally binding benefit-sharing provisions, often emphasizing principles of common heritage and solidarity. Their primary concern remains ensuring concrete mechanisms for technology transfer, local manufacturing, and equitable access to countermeasures, asserting that without such guarantees, the incentive to share pathogens diminishes significantly. Conversely, some developed nations and pharmaceutical industry representatives prioritize maintaining strong intellectual property protections and fostering an environment conducive to private sector innovation. While acknowledging the need for global cooperation, they often advocate for voluntary contributions and market-based solutions, expressing concerns that overly prescriptive benefit-sharing mechanisms could stifle research and development. Public health NGOs and civil society organizations universally champion the strongest possible equity provisions, advocating for transparency, accountability, and a framework that explicitly prioritizes public health over commercial interests, pushing for robust public financing mechanisms and clear pathways for technology transfer.

The Imperative for Equity: Learning from Past Pandemics

The quest for an equitable PABS system is deeply rooted in historical experiences and the profound inequalities exposed during health emergencies. The 2009 H1N1 influenza pandemic, for example, highlighted early challenges in vaccine access, but the scale of inequity during COVID-19 was unprecedented. Beyond vaccine distribution, the disparities extended to diagnostic tests, therapeutics, and even basic medical supplies like oxygen and PPE. Low-income countries often waited months, if not years, for essential supplies that were readily available in wealthier nations. This imbalance not only resulted in higher mortality rates in vulnerable populations but also prolonged the global pandemic, as uncontrolled outbreaks in some regions became breeding grounds for new variants that could then spread worldwide.

The PABS annex, therefore, is not merely a technical document; it represents a commitment to fundamentally reshape the global health architecture to prevent a repeat of these failures. It seeks to operationalize the principle that a pathogen anywhere is a threat everywhere, and that the response must be a shared responsibility with shared benefits. The economic implications of such an agreement are vast. The World Bank estimated that the global cost of the COVID-19 pandemic could reach $16 trillion, highlighting the immense economic benefits of preventing or mitigating future pandemics. An equitable PABS system, by fostering rapid data sharing and widespread access to countermeasures, could significantly reduce the human and economic toll of future outbreaks.

Looking Ahead: Implications for Global Health Security and Future Generations

Finalizing the PABS annex is a critical step towards enabling countries to consider the signature and ratification of the entire WHO Pandemic Agreement. This comprehensive agreement holds profound implications for global health security, aiming to create a more resilient, responsive, and equitable international framework for pandemic prevention, preparedness, and response for future generations. It promises to rebuild trust among nations, which was severely eroded during COVID-19, particularly between the Global North and South. By establishing clear rules and mechanisms for sharing both pathogens and their benefits, the agreement seeks to transform a fragmented and often competitive response into a truly cooperative endeavor.

The successful implementation of PABS would foster unprecedented scientific collaboration, enabling researchers worldwide to rapidly access critical biological samples and sequence data, accelerating the development of new diagnostics, treatments, and vaccines. It could also stimulate local manufacturing capabilities in developing countries, reducing their reliance on external supply chains and enhancing regional self-sufficiency, a vital component of true preparedness. This shift towards greater equity and shared responsibility is expected to yield a faster, more coordinated, and ultimately less catastrophic response to future pandemics, mitigating the massive human and economic disruptions witnessed in recent years.

The Road to Ratification: Remaining Challenges and the Path Forward

Despite the significant progress made during the seventh IGWG meeting, substantial challenges remain on the path to finalizing the PABS annex and the broader Pandemic Agreement. Bridging the divide on issues such as intellectual property rights, mandatory technology transfer, the exact definition and scope of "benefits," and sustainable financing mechanisms will require sustained political will and flexibility from all Member States. The goal is to create a legally binding instrument that balances national sovereignty with global health imperatives, a task that demands delicate diplomatic navigation.

The IGWG is scheduled to hold its eighth and likely final meeting from April 29 to May 10, 2024, with the ambitious goal of presenting a finalized draft of the Pandemic Agreement to the 77th World Health Assembly in May 2024 for consideration and potential adoption. This timeline underscores the urgency articulated by Dr. Tedros and the co-chairs. Achieving consensus among 194 Member States on such a complex and far-reaching instrument will be a testament to multilateralism and a defining moment for global health governance. The successful conclusion of these negotiations and the subsequent ratification of the WHO Pandemic Agreement, with a robust and equitable PABS annex, would represent a landmark achievement, fundamentally strengthening the world’s collective ability to face the inevitable challenges of future pandemics.